> 0 1 0 1 O
65 2 4 2 4 B-lower_bound
years 5 10 5 10 I-lower_bound
not 11 14 11 14 O
previously 15 25 15 25 O
treated 26 33 26 33 O
for 34 37 34 37 O
AML 38 41 38 41 B-cancer
and 42 45 42 45 O
who 46 49 46 49 O
are 50 53 50 53 O
not 54 57 54 57 O
candidates 58 68 58 68 O
for 69 72 69 72 O
intensive 73 82 73 82 B-treatment
chemotherapy 83 95 83 95 I-treatment
nor 96 99 96 99 O
candidates 100 110 100 110 O
for 111 114 111 114 O
established 115 126 115 126 O
alternative 127 138 127 138 O
chemotherapy 139 151 139 151 O
Or 152 154 152 154 O
Patients 155 163 155 163 O
with 164 168 164 168 O
cytologically 169 182 169 182 O
confirmed 183 192 183 192 O
and 193 196 193 196 O
documented 197 207 197 207 O
MDS 208 211 208 211 B-cancer
) 211 212 211 212 O
, 212 213 212 213 O
in 214 216 214 216 O
relapse 217 224 217 224 O
or 225 227 225 227 O
refractory 228 238 228 238 O
after 239 244 239 244 O
previous 245 253 245 253 O
treatment 254 263 254 263 B-treatment
line 264 268 264 268 O
including 269 278 269 278 O
at 279 281 279 281 O
least 282 287 282 287 O
one 288 291 288 291 O
hypomethylating 292 307 292 307 B-treatment
agent 308 313 308 313 I-treatment
and 314 317 314 317 O
have 318 322 318 322 O
≥10 323 326 323 326 O
% 326 327 326 327 I-lower_bound
bone 328 332 328 332 B-clinical_variable
marrow 333 339 333 339 I-clinical_variable
blasts 340 346 340 346 I-clinical_variable

AST 0 3 347 350 B-clinical_variable
and 4 7 351 354 O
ALT 8 11 355 358 B-clinical_variable
≤ 12 13 359 360 O
1.5 14 17 361 364 B-upper_bound
x 18 19 365 366 I-upper_bound
ULN 20 23 367 370 I-upper_bound

Male 0 4 371 375 B-gender

Pregnancy 0 9 376 385 B-pregnancy

Presence 0 8 386 394 O
of 9 11 395 397 O
≥ 12 13 398 399 O
CTCAE 14 19 400 405 B-clinical_variable
grade 20 25 406 411 B-lower_bound
2 26 27 412 413 I-lower_bound
toxicity 28 36 414 422 O
( 37 38 423 424 O
except 38 44 424 430 O
alopecia 45 53 431 439 B-chronic_disease
of 54 56 440 442 O
any 57 60 443 446 O
grade 61 66 447 452 O
) 66 67 452 453 O
due 68 71 454 457 O
to 72 74 458 460 O
prior 75 80 461 466 B-treatment
cancer 81 87 467 473 I-treatment
therapy 88 95 474 481 I-treatment
, 95 96 481 482 O
according 97 106 483 492 O
to 107 109 493 495 O
the 110 113 496 499 O
National 114 122 500 508 O
Cancer 123 129 509 515 O
Institute 130 139 516 525 O
Common 140 146 526 532 O
Terminology 147 158 533 544 O
Criteria 159 167 545 553 O
for 168 171 554 557 O
Adverse 172 179 558 565 O
Events 180 186 566 572 O
( 187 188 573 574 O
NCI 188 191 574 577 O
- 191 192 577 578 O
CTCAE 192 197 578 583 O
, 197 198 583 584 O
version 199 206 585 592 O
4.03 207 211 593 597 O
) 211 212 597 598 O

Serum 0 5 599 604 B-clinical_variable
CK 6 8 605 607 I-clinical_variable
/ 8 9 607 608 I-clinical_variable
CPK 9 12 608 611 I-clinical_variable
≤2.5 13 17 612 616 O
x 18 19 617 618 I-upper_bound
ULN 20 23 619 622 I-upper_bound

Serum 0 5 623 628 B-clinical_variable
creatinine 6 16 629 639 I-clinical_variable
≤ 17 18 640 641 O
1.5 19 22 642 645 B-upper_bound
x 23 24 646 647 I-upper_bound
ULN 25 28 648 651 I-upper_bound
( 29 30 652 653 I-upper_bound
upper 30 35 653 658 I-upper_bound
normal 36 42 659 665 I-upper_bound
limit 43 48 666 671 I-upper_bound
) 48 49 671 672 I-upper_bound
or 50 52 673 675 O
calculated 53 63 676 686 B-clinical_variable
creatinine 64 74 687 697 I-clinical_variable
clearance 75 84 698 707 I-clinical_variable
( 85 86 708 709 O
determined 86 96 709 719 O
by 97 99 720 722 O
MDRD 100 104 723 727 O
) 104 105 727 728 O
> 106 107 729 730 O
50 108 110 731 733 B-lower_bound
mL 111 113 734 736 I-lower_bound
/ 113 114 736 737 I-lower_bound
min/1.73m2 114 124 737 747 I-lower_bound

Total 0 5 748 753 O
bilirubin 6 15 754 763 B-clinical_variable
level 16 21 764 769 I-clinical_variable
≤ 22 23 770 771 O
1.5 24 27 772 775 O
x 28 29 776 777 O
ULN 30 33 778 781 O
, 33 34 781 782 O
except 35 41 783 789 O
for 42 45 790 793 O
patients 46 54 794 802 O
with 55 59 803 807 O
known 60 65 808 813 O
Gilbert 66 73 814 821 B-chronic_disease
's 73 75 821 823 I-chronic_disease
syndrome 76 84 824 832 I-chronic_disease
( 85 86 833 834 O
confirmed 86 95 834 843 O
by 96 98 844 846 O
the 99 102 847 850 O
UGT1A1 103 109 851 857 O
polymorphism 110 122 858 870 O
analysis 123 131 871 879 O
) 131 132 879 880 O
, 132 133 880 881 O
who 134 137 882 885 O
are 138 141 886 889 O
excluded 142 150 890 898 O
if 151 153 899 901 O
total 154 159 902 907 O
bilirubin>3.0 160 173 908 921 O
x 174 175 922 923 I-lower_bound
ULN 176 179 924 927 I-lower_bound
or 180 182 928 930 O
direct 183 189 931 937 O
bilirubin 190 199 938 947 O
> 200 201 948 949 O
1.5 202 205 950 953 O
x 206 207 954 955 O
ULN 208 211 956 959 O

Uncontrolled 0 12 960 972 B-chronic_disease
hepatitis 13 22 973 982 I-chronic_disease
B 23 24 983 984 I-chronic_disease
or 25 27 985 987 I-chronic_disease
C 28 29 988 989 I-chronic_disease
infection 30 39 990 999 I-chronic_disease

active 0 6 1000 1006 O
or 7 9 1007 1009 O
chronic 10 17 1010 1017 B-chronic_disease
pancreatitis 18 30 1018 1030 I-chronic_disease

aged 0 4 1031 1035 B-age
≥ 5 6 1036 1037 O
18 7 9 1038 1040 B-lower_bound
years 10 15 1041 1046 I-lower_bound

already 0 7 1047 1054 O
enrolled 8 16 1055 1063 O
in 17 19 1064 1066 O
the 20 23 1067 1070 O
study 24 29 1071 1076 O
who 30 33 1077 1080 O
has 34 37 1081 1084 O
received 38 46 1085 1093 O
at 47 49 1094 1096 O
least 50 55 1097 1102 O
one 56 59 1103 1106 B-lower_bound
S64315 60 66 1107 1113 B-treatment
infusion 67 75 1114 1122 I-treatment

arriers 0 7 1123 1130 O
of 8 10 1131 1133 O
HIV 11 14 1134 1137 B-chronic_disease
antibodies 15 25 1138 1148 O

female 0 6 1149 1155 B-gender

history 0 7 1156 1163 O
of 8 10 1164 1166 O
significant 11 22 1167 1178 O
liver 23 28 1179 1184 B-chronic_disease
disease 29 36 1185 1192 I-chronic_disease

myocardial 0 10 1193 1203 B-chronic_disease
infarction 11 21 1204 1214 I-chronic_disease
( 22 23 1215 1216 I-chronic_disease
MI 23 25 1216 1218 I-chronic_disease
) 25 26 1218 1219 I-chronic_disease
, 26 27 1219 1220 O
angina 28 34 1221 1227 B-chronic_disease
pectoris 35 43 1228 1236 I-chronic_disease
, 43 44 1236 1237 O
coronary 45 53 1238 1246 B-treatment
artery 54 60 1247 1253 I-treatment
bypass 61 67 1254 1260 I-treatment
graft 68 73 1261 1266 I-treatment
( 74 75 1267 1268 I-treatment
CABG 75 79 1268 1272 I-treatment
) 79 80 1272 1273 I-treatment
within 81 87 1274 1280 O
6 88 89 1281 1282 B-upper_bound
months 90 96 1283 1289 I-upper_bound
prior 97 102 1290 1295 I-upper_bound
to 103 105 1296 1298 O
starting 106 114 1299 1307 O
study 115 120 1308 1313 O
treatment 121 130 1314 1323 B-treatment

secondary 0 9 1324 1333 O
to 10 12 1334 1336 O
MDS 13 16 1337 1340 B-cancer
treated 17 24 1341 1348 O
at 25 27 1349 1351 O
least 28 33 1352 1357 O
by 34 36 1358 1360 O
hypomethylating 37 52 1361 1376 B-treatment
agent 53 58 1377 1382 I-treatment

with 0 4 1383 1387 O
relapsed 5 13 1388 1396 B-chronic_disease
or 14 16 1397 1399 I-chronic_disease
refractory 17 27 1400 1410 I-chronic_disease
disease 28 35 1411 1418 I-chronic_disease
without 36 43 1419 1426 O
established 44 55 1427 1438 O
alternative 56 67 1439 1450 B-treatment
therapy 68 75 1451 1458 I-treatment

